ibritumomab tiuxetan pronounced ɪbrɪˈtuːmoʊmæb sold trade name zevalin monoclonal antibody radioimmunotherapy treatment nonhodgkins lymphoma drug uses monoclonal mouse antibody ibritumomab conjunction chelator tiuxetan radioactive isotope either added tiuxetan modified version dtpa whose carbon backbone contains isothiocyanatobenzyl methyl ibritumomab used treat relapsed refractory low grade transformed b cell nonhodgkins lymphoma nhl lymphoproliferative disorder previously untreated follicular nhl adult patients achieve partial complete response firstline treatment administered patients lymphoma marrow involvement andor impaired bone marrow treatment starts infusions rituximab may followed administration labelled ibritumomab tiuxetan replaces component allow distribution drug imaged gamma camera actual therapy administered seven nine days later second infusion rituximab given followed tiuxetan intravenous infusion around minutes radioactive activity determined based patient body weight platelet antibody binds antigen found surface normal malignant b cells b cell precursors allowing radiation attached isotope mostly beta emission kill nearby cells addition antibody may trigger cell death via antibodydependent cellmediated cytotoxicity adcc complementdependent cytotoxicity cdc apoptosis together actions eliminate b cells body allowing new population healthy b cells develop lymphoid stem developed idec pharmaceuticals part biogen ibritumomab tiuxetan first radioimmunotherapy drug approved food drug administration fda treat cancer approved treatment patients relapsed refractory follicular lymphoma nhl including patients rituximab refractory follicular given marketing authorisation european medicines agency treatment adult patients rituximab relapsed refractory follicular bcell nonhodgkins september ibritumomab received approval fda expanded label include previously untreated patients chemotherapy ibritumomab currently patent protection available generic form first approved expensive drug available given single dose costing average however ibritumomab essentially entire course lymphoma therapy delivered days one visit predosing rituxan one visit week later actual zevalin therapeutic dose preceded rituxan compared monoclonal antibody treatments many well course therapy may considered cost httpsenwikipediaorgwikiibritumomabtiuxetan